PET imaging of early response to the tyrosine kinase inhibitor ZD4190

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 7, 2011, Pages 1237-1247

  Yang, Min ^a,b   Gao, Haokao ^b,c   Yan, Yongjun ^b   Sun, Xilin ^b   Chen, Kai ^b   Quan, Qimeng ^b   Lang, Lixin ^b   Kiesewetter, Dale ^b   Niu, Gang ^b   Chen, Xiaoyuan ^b  

^a BEIJING HOSPITAL   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

18F FDG; 18F FLT; 18F FPPRGD2; Antiangiogenic treatment; Integrin; Positron emission tomography (PET); Therapy response; Tyrosine kinase inhibitor

Indexed keywords

BETA3 INTEGRIN; FLUORODEOXYGLUCOSE F 18; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SCREENING; EX VIVO STUDY; GLUCOSE METABOLISM; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; TUMOR; TUMOR CELL; TUMOR GROWTH;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GLUCOSE; HUMANS; INTEGRIN ALPHAVBETA3; MICE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOACTIVE TRACERS; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958036678     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1742-z     Document Type: Article

References (48)

1. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 10.1056/NEJM197108122850711 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
2. N Ferrara 2002 VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 795 803 12360282 10.1038/nrc909 1:CAS:528:DC%2BD38XnsVGrtbk%3D (Pubitemid 37328914)
3. J Sun DA Wang RK Jain A Carie S Paquette E Ennis, et al. 2005 Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors Oncogene 24 4701 4709 15897913 10.1038/sj.onc.1208391 1:CAS:528:DC%2BD2MXlvVGhs7k%3D (Pubitemid 41032606)
4. H Watanabe AJ Mamelak B Wang BG Howell I Freed C Esche, et al. 2004 Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity Exp Dermatol 13 671 681 15500639 10.1111/j.0906-6705.2004.00240.x 1:CAS:528:DC%2BD2cXhtVKis7%2FN (Pubitemid 39481020)
5. M Prewett J Huber Y Li A Santiago W O'Connor K King, et al. 1999 Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors Cancer Res 59 5209 5218 10537299 1:CAS:528:DyaK1MXmvFelsLo%3D (Pubitemid 29503984)
6. F Ciardiello R Caputo V Damiano T Troiani D Vitagliano F Carlomagno, et al. 2003 Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin Cancer Res 9 1546 1556 12684431 1:CAS:528:DC%2BD3sXislerur8%3D (Pubitemid 36418413)
7. SR Wedge DJ Ogilvie M Dukes J Kendrew JO Curwen LF Hennequin, et al. 2000 ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy Cancer Res 60 970 975 10706112 1:CAS:528:DC%2BD3cXhs1Shs7o%3D (Pubitemid 30129533)
8. J Drevs I Hofmann H Hugenschmidt C Wittig H Madjar M Muller, et al. 2000 Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model Cancer Res 60 4819 4824 10987292 1:CAS:528:DC%2BD3cXmsFWhs7g%3D
9. S Faivre S Djelloul E Raymond 2006 New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors Semin Oncol 33 407 420 16890796 10.1053/j.seminoncol.2006.04.005 1:CAS:528:DC%2BD28XpsVersb4%3D (Pubitemid 44142738)
10. QD Nguyen S Rodrigues CM Rodrigue C Rivat C Grijelmo E Bruyneel, et al. 2006 Inhibition of vascular endothelial growth factor VEGF165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts Mol Cancer Ther 5 2070 2077 16928828 10.1158/1535-7163.MCT-06-0044 1:CAS:528:DC%2BD28XosVansLc%3D (Pubitemid 44336579)
11. CC Jaffe 2006 Measures of response: RECIST, WHO, and new alternatives J Clin Oncol 24 3245 3251 16829648 10.1200/JCO.2006.06.5599 (Pubitemid 46622065)
12. MH Michalski X Chen 2011 Molecular imaging in cancer treatment Eur J Nucl Med Mol Imaging 38 358 377 20661557 10.1007/s00259-010-1569-z 1:CAS:528:DC%2BC3MXpsFKjsw%3D%3D
13. CG Willett Y Boucher E di Tomaso DG Duda LL Munn RT Tong, et al. 2004 Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 145 147 14745444 10.1038/nm988 1:CAS:528:DC%2BD2cXoslKmtQ%3D%3D (Pubitemid 38524883)
14. Y Fujio K Walsh 1999 Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner J Biol Chem 274 16349 16354 10347193 10.1074/jbc.274.23.16349 1:CAS:528:DyaK1MXjs1Onsbg%3D (Pubitemid 29269345)
15. L Hlatky P Hahnfeldt J Folkman 2002 Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us J Natl Cancer Inst 94 883 893 12072542 (Pubitemid 34778087)
16. CJ Hoekstra SG Stroobants OS Hoekstra EF Smit JF Vansteenkiste AA Lammertsma 2002 Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography Clin Cancer Res 8 2109 2115 12114410 (Pubitemid 34753580)
17. MS Hughes JN Marsh H Zhang AK Woodson JS Allen EK Lacy, et al. 2006 Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo IEEE Trans Ultrason Ferroelectr Freq Control 53 1609 1616 16964911 10.1109/TUFFC.2006.1678189 (Pubitemid 44335169)
18. AR Padhani 2003 MRI for assessing antivascular cancer treatments Br J Radiol 76 S60 S80 15456715 10.1259/bjr/15334380 (Pubitemid 39530317)
19. GM Tozer 2003 Measuring tumour vascular response to antivascular and antiangiogenic drugs Br J Radiol 76 S23 S35 15456711 10.1259/bjr/30165281 1:CAS:528:DC%2BD2cXhtFakurrF (Pubitemid 39530313)
20. G Niu X Chen 2010 Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy Curr Drug Targets 11 1000 1117 20426765 10.2174/138945010791591395 1:CAS:528:DC%2BC3cXhtVCkurzI
21. O Warburg 1956 On the origin of cancer cells Science 123 309 314 13298683 10.1126/science.123.3191.309 1:STN:280:DyaG28%2FltV2ktQ%3D%3D
22. JL Sherley TJ Kelly 1988 Regulation of human thymidine kinase during the cell cycle J Biol Chem 263 8350 8358 3372530 1:CAS:528:DyaL1cXkt1SqsLs%3D
23. BP Eliceiri DA Cheresh 1999 The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development J Clin Invest 103 1227 1230 10225964 10.1172/JCI6869 1:CAS:528:DyaK1MXivFansrs%3D (Pubitemid 29218291)
24. M Friedlander CL Theesfeld M Sugita M Fruttiger MA Thomas S Chang, et al. 1996 Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases Proc Natl Acad Sci U S A 93 9764 9769 8790405 10.1073/pnas.93.18.9764 1:CAS:528:DyaK28XlsFehsbs%3D (Pubitemid 26296683)
25. AJ Beer R Haubner I Wolf M Goebel S Luderschmidt M Niemeyer, et al. 2006 PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging αvβ3 expression J Nucl Med 47 763 769 16644745 1:CAS:528: DC%2BD28XltFaiurw%3D (Pubitemid 46768438)
26. LM Kenny RC Coombes I Oulie KB Contractor M Miller TJ Spinks, et al. 2008 Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients J Nucl Med 49 879 886 18483090 10.2967/jnumed.107.049452 (Pubitemid 351793427)
27. LF Hennequin AP Thomas C Johnstone ES Stokes PA Ple JJ Lohmann, et al. 1999 Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors J Med Chem 42 5369 5389 10639280 10.1021/jm990345w 1:CAS:528:DyaK1MXnvVCmur4%3D (Pubitemid 30036772)
28. SJ Lee SJ Oh DY Chi HS Kil EN Kim JS Ryu, et al. 2007 Simple and highly efficient synthesis of 3'-deoxy-3'-[18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent Eur J Nucl Med Mol Imaging 34 1406 1409 17384949 10.1007/s00259-007-0391-8 1:CAS:528:DC%2BD2sXpsVarurg%3D (Pubitemid 47312587)
29. S Liu Z Liu K Chen Y Yan P Watzlowik HJ Wester, et al. 2010 18F-labeled galacto and PEGylated RGD dimers for PET Imaging of αvβ3 integrin expression Mol Imaging Biol 12 530 538 19949981 10.1007/s11307-009-0284-2
30. T Higashi N Tamaki T Honda T Torizuka T Kimura T Inokuma, et al. 1997 Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study J Nucl Med 38 1337 1344 9293783 1:CAS:528:DyaK2sXmt1Slu7k%3D (Pubitemid 27386185)
31. H van Cruijsen A van der Veldt K Hoekman 2009 Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions Front Biosci 14 2248 2268 19273199 10.2741/3377
32. RS Herbst NA Mullani DW Davis KR Hess DJ McConkey C Charnsangavej, et al. 2002 Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin J Clin Oncol 20 3804 3814 12228200 10.1200/JCO.2002.05.102 1:CAS:528: DC%2BD38XntVyns7o%3D
33. WA Weber 2010 Monitoring tumor response to therapy with 18F-FLT PET J Nucl Med 51 841 844 20484418 10.2967/jnumed.109.071217
34. S Apisarnthanarax MM Alauddin F Mourtada H Ariga U Raju O Mawlawi, et al. 2006 Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models Clin Cancer Res 12 4590 4597 16899606 10.1158/1078-0432.CCR-05-2720 1:CAS:528:DC%2BD28XnvVGks74%3D (Pubitemid 44297809)
35. J Leyton JR Latigo M Perumal H Dhaliwal Q He EO Aboagye 2005 Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo Cancer Res 65 4202 4210 15899811 10.1158/0008-5472.CAN-04-4008 1:CAS:528:DC%2BD2MXktlSmtrs%3D (Pubitemid 40775658)
36. LH Wei H Su IJ Hildebrandt ME Phelps J Czernin WA Weber 2008 Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma Clin Cancer Res 14 3416 3426 18519772 10.1158/1078-0432.CCR-07-1824 1:CAS:528:DC%2BD1cXmslygsbs%3D
37. AF Shields JM Lawhorn-Crews DA Briston S Zalzala S Gadgeel KA Douglas, et al. 2008 Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer Clin Cancer Res 14 4463 4468 18628460 10.1158/1078-0432.CCR-07-5243 1:CAS:528:DC%2BD1cXosFGit7Y%3D
38. AJ de Langen B Klabbers M Lubberink R Boellaard MD Spreeuwenberg BJ Slotman, et al. 2009 Reproducibility of quantitative 18F-3'-deoxy-3'- fluorothymidine measurements using positron emission tomography Eur J Nucl Med Mol Imaging 36 389 395 18931838 10.1007/s00259-008-0960-5
39. W Cai SS Gambhir X Chen 2005 Multimodality tumor imaging targeting integrin αvβ3 Biotechniques 39 S14 S25 20158499 10.2144/000112091
40. MS Morrison SA Ricketts J Barnett A Cuthbertson J Tessier SR Wedge 2009 Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy J Nucl Med 50 116 122 19091899 10.2967/jnumed.108.056077 1:CAS:528:DC%2BD1MXhvFCjt7s%3D
41. BJ McParland MP Miller TJ Spinks LM Kenny S Osman MK Khela, et al. 2008 The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers J Nucl Med 49 1664 1687 18794263 10.2967/jnumed.108.052126
42. AJ Beer R Haubner M Sarbia M Goebel S Luderschmidt AL Grosu, et al. 2006 Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin αvβ3 expression in man Clin Cancer Res 12 3942 3949 16818691 10.1158/1078-0432.CCR-06-0266 1:CAS:528:DC%2BD28XmsValtLk%3D (Pubitemid 44078079)
43. 18F]FPPRGD2: A novel PET radiopharmaceutical for imaging αvβ3 integrin levels. Radiology. In press.
44. KH Jung KH Lee JY Paik BH Ko JS Bae BC Lee, et al. 2006 Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy J Nucl Med 47 2000 2007 17138743 1:CAS:528:DC%2BD2sXksFKgug%3D%3D
45. RA Dumont I Hildebrandt H Su R Haubner G Reischl JG Czernin, et al. 2009 Noninvasive imaging of αvβ3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib Cancer Res 69 3173 3179 19318569 10.1158/0008-5472.CAN-08-3390 1:CAS:528:DC%2BD1MXjvVWit7s%3D
46. X Sun Y Yan S Liu Q Cao M Yang N Neamati B Shen G Niu X Chen 2011 18F-FPPRGD2 and 18F-FDG PET imaging of Abraxane therapy response J Nucl Med 52 140 146 21149494 10.2967/jnumed.110.080606
47. M Dandekar JR Tseng SS Gambhir 2007 Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts J Nucl Med 48 602 607 17401098 10.2967/jnumed.106.036608 (Pubitemid 47571417)
48. 18F]FPPRGD2 uptake in murine models of human tumor xenografts. Eur J Nucl Med Mol Imaging. 2010. doi: 10.1007/s00259-010-1672-1.